Surprise phase III failure for ZD1839

Lancet Oncol. 2002 Oct;3(10):583. doi: 10.1016/s1470-2045(02)00883-5.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Cisplatin / administration & dosage
  • Cisplatin / pharmacology
  • Clinical Trials, Phase III as Topic
  • Epidermal Growth Factor / antagonists & inhibitors
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quality of Life
  • Quinazolines / pharmacology*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Epidermal Growth Factor
  • Protein-Tyrosine Kinases
  • Cisplatin
  • Gefitinib